lots of words but this is all I will really remember
1. the FDA meeting IS this month (when this month, I do not know)
2. assuming FDA positively winks at AA app, the company is committed to go gangbusters on manufacturing ramp (which tells me the process is in place right now but will not fully be implemented without the positive FDA AA wink)
3. based on what the CEO said, seems to me we will know company's intentions on AA by no later than end of april, and possibly much sooner, depending upon exactly when the FDA meeting is
4. CEO's collective comments and non comments on 74 week data literally confirm the data is at minimum, good
as to speculation, I interpret the guide to the humongified manu ramp expense as a signal that the CEO feels good about the AA opportunity
Already one analyst gave his comments this morning. I agree there should be more positive comments tomorrow.
Sarepta DMD drug still has accelerated approval potential, says Piper Jaffray
Piper Jaffray said it still believes there is a 50/50 chance that Sarepta will be able to file for approval of its Duchenne Muscular Dystrophy drug eteplirsen with its existing data. Piper said that if the company is required to conduct a larger trial prior to filing, a slide in the stock would be likely but would present a buying opportunity. The firm maintains an Overweight rating and $35 price target on Sarepta. :
Pre reverse split, that comes to 26 and change. Though I feel 60 to 80 is more comprehensible, 160 is not impossible. When I was a child, Jerry Lewis Telethons were praying for Miracles in DMD....don't forget how far we have come.